Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 4 de 4
Filtre
Ajouter des filtres








Gamme d'année
1.
Experimental & Molecular Medicine ; : 303-309, 2001.
Article Dans Anglais | WPRIM | ID: wpr-144625

Résumé

Both Fas and PMA can activate phospholipase D via activation of protein kinase Cbeta in A20 cells. Phospholipase D activity was increased 4 fold in the presence of Fas and 2.5 fold in the presence of PMA. The possible involvement of tyrosine phosphorylation in Fas-induced activation of phospholipase D was investigated. In five minute after Fas cross-linking, there was a prominent increase in tyrosine phosphorylated proteins, and it was completely inhibited by D609, a specific inhibitor of phosphatidylcholine-specific phospholipase C (PC-PLC). A tyrosine kinase inhibitor, genistein, can partially inhibit Fas-induced phospholipase D activation. There were no effects of genistein on Fas-induced activation of PC-PLC and protein kinase C. These results strongly indicate that tyrosine phosphorylation may in part account for the increase in phospholipase D activity by Fas cross-linking and D609 can block not only PC-PLC activity but also tyrosine phosphorylation involved in Fas-induced phospholipase D activation.


Sujets)
Souris , Animaux , Anticorps monoclonaux/immunologie , Antigènes CD95/immunologie , Composés pontés/pharmacologie , Lignée cellulaire , Réactifs réticulants , Relation dose-réponse (immunologie) , Activation enzymatique , Génistéine/pharmacologie , Hydrolyse , Lymphomes/anatomopathologie , Type C Phospholipases/antagonistes et inhibiteurs , Phospholipase D/métabolisme , Phosphorylation , Phosphoryl-choline/métabolisme , Solubilité , Thiones/pharmacologie , Cellules cancéreuses en culture , Tyrosine/métabolisme , Eau/composition chimique
2.
Experimental & Molecular Medicine ; : 303-309, 2001.
Article Dans Anglais | WPRIM | ID: wpr-144612

Résumé

Both Fas and PMA can activate phospholipase D via activation of protein kinase Cbeta in A20 cells. Phospholipase D activity was increased 4 fold in the presence of Fas and 2.5 fold in the presence of PMA. The possible involvement of tyrosine phosphorylation in Fas-induced activation of phospholipase D was investigated. In five minute after Fas cross-linking, there was a prominent increase in tyrosine phosphorylated proteins, and it was completely inhibited by D609, a specific inhibitor of phosphatidylcholine-specific phospholipase C (PC-PLC). A tyrosine kinase inhibitor, genistein, can partially inhibit Fas-induced phospholipase D activation. There were no effects of genistein on Fas-induced activation of PC-PLC and protein kinase C. These results strongly indicate that tyrosine phosphorylation may in part account for the increase in phospholipase D activity by Fas cross-linking and D609 can block not only PC-PLC activity but also tyrosine phosphorylation involved in Fas-induced phospholipase D activation.


Sujets)
Souris , Animaux , Anticorps monoclonaux/immunologie , Antigènes CD95/immunologie , Composés pontés/pharmacologie , Lignée cellulaire , Réactifs réticulants , Relation dose-réponse (immunologie) , Activation enzymatique , Génistéine/pharmacologie , Hydrolyse , Lymphomes/anatomopathologie , Type C Phospholipases/antagonistes et inhibiteurs , Phospholipase D/métabolisme , Phosphorylation , Phosphoryl-choline/métabolisme , Solubilité , Thiones/pharmacologie , Cellules cancéreuses en culture , Tyrosine/métabolisme , Eau/composition chimique
3.
Experimental & Molecular Medicine ; : 42-46, 1999.
Article Dans Anglais | WPRIM | ID: wpr-186198

Résumé

Our previous studies have shown that subthreshold concentrations of two platelet agonists exert synergistic effects on platelet aggregation. Here we studied the mechanism of synergistic interaction of 5-hydroxytryptamine (5-HT) and epinephrine mediated platelet aggregation. We show that 5-HT had no or little effect on aggregation but it did potentiate the aggregation response of epinephrine. The synergistic interaction of 5-HT (1-5 microM) and epinephrine (0.5-2 microM) was inhibited by alpha2-adrenoceptor blocker (yohimbine; IC50= 0.4 microM), calcium channel blockers (verapamil and diltiazem with IC50 of 10 and 48 mM, respectively), PLC inhibitor (U73122; IC50=6 microM) and nitric oxide (NO) donor, SNAP (IC50=1.6 microM)). The data suggest that synergistic effects of platelet agonists are receptor-mediated and occur through multiple signalling pathways including the activation PLC/Ca2+ signalling cascades.


Sujets)
Humains , Technique de Western , Inhibiteurs des canaux calciques/pharmacologie , Signalisation calcique , Synergie des médicaments , Activation enzymatique , Antienzymes/pharmacologie , Épinéphrine/pharmacologie , Sous-unités alpha Gi-Go des protéines G/métabolisme , Protéines G/métabolisme , Type C Phospholipases/métabolisme , Type C Phospholipases/antagonistes et inhibiteurs , Agrégation plaquettaire/physiologie , Agrégation plaquettaire/effets des médicaments et des substances chimiques , Sérotonine/pharmacologie , Transduction du signal
SÉLECTION CITATIONS
Détails de la recherche